De novo design of immunoglobulin-like domains Tamuka M. Chidyausiku, Soraia R. Mendes, Jason C. Klima, Marta Nadal, Ulrich Eckhard, Jorge Roel-Touris, Scott Houliston, Tibisay Guevara, Hugh K. Haddox, Adam Moyer, Cheryl H. Arrowsmith, F. Xavier Gomis-Rüth, David Ba...
The immunoglobulin domain framework of antibodies has been a long standing design challenge. Here, the authors describe design rules for tailoring these domains and show they can be accurately designed, de novo, with high stability and the ability to scaffold functional loops.Chidyausiku, ...
De novo design of proteins housing excitonically coupled chlorophyll special pairs Nathan M. Ennist Shunzhi Wang David Baker Nature Chemical Biology (2024) De novo design of immunoglobulin-like domains Tamuka M. Chidyausiku Soraia R. Mendes Enrique Marcos Nature Communications (2022)Download...
The de novo design of protein-protein interfaces is a stringent test of our understanding of the principles underlying protein-protein interactions and would enable unique approaches to biological and medical challenges. Here we describe a motif-based method to computationally design protein-protein compl...
immunoglobulin G (IgG) molecule, where the receptor-binding moiety from a RaPID peptide can be inserted into a loop location chosen from up to 8 locations to yield 8 different antibody-like bivalent binders comprising a single subunit (heavy chain) with a size one-third of IgG (Figure 1A)....
The promise of biopharmaceuticals comprising one or more binding domains motivates the development of novel methods for de novo isolation and affinity maturation of virion-binding domains. Identifying avenues for overcoming the challenges associated with using virions as screening reagents is paramount given...
(2022) Novel Loss of Function (G15D) Mutation on RAC2 in a Family with Combined Immunodeficiency and Increased Levels of Immunoglobulin G, A, and E. J Clin Immunol Dec 2 doi: 10.1007/s10875-022-01411-5. 2022 Son...
Clostridioides difficile toxin B (TcdB) is the key virulence factor accounting for C. difficile infection-associated symptoms. Effectively neutralizing different TcdB variants with a universal solution poses a significant challenge. Here we present the d
De novo design of highly selective miniprotein inhibitors of integrins αvβ6 and αvβ8 Anindya Roy, Lei Shi, Ashley Chang, Xianchi Dong, Andres Fernandez, John C. Kraft, Jing Li, Viet Q. Le, Rebecca Viazzo Winegar, Gerald Maxwell Cherf, Dean Slocum, P. Daniel Pouls...
De Novo Submission Update, 4/18/24: While Key Proteo intended to submit its first newborn screening kit to the FDA on 3/29/24, a software issue was identified in the final review of the application and has delayed the submission. Key Proteo would like to ...